ClinicalTrials.gg
CompletedNCT04780165Updated Mar 3, 2021

Efficacy and Tolerability of Blephademodex Wipes

An interventional study of Blephademodex in Demodex Blepharitis, sponsored by Laboratoires Thea. Completed at 1 site in Germany. Per ClinicalTrials.gov, last updated 2021-03-03.

Sponsored by Laboratoires Thea · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Sep 2019, registered Sep 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Sex
All
01

Study summary

Primary Objective

  • To evaluate efficacy of Blephademodex eyelid hygiene wipe treatment with a subsequent maintenance period with Blephaclean lid cleansing wipes in Demodex blepharitis, as assessed by the change in ocular symptoms by a Global Discomfort Scale (GDS).

Secondary Objectives

  • To evaluate the efficacy of Blephademodex eyelid hygiene wipe treatment in Demodex blepharitis as assessed by the change alone and in combination with a subsequent maintenance period of treatment with Blephaclean eyelid cleansing wipes ocular symptoms by: adapted TOSS; SANDE; specific blepharitis symptoms; Demodex count; ocular surface redness (Efron scale); lid margin redness/swelling (Efron / custom scale); Dandruff coverage at bases of eyelashes; ocular surface staining (Oxford scale; corneal only)
  • To evaluate subject and physician satisfaction with Blephademodex eyelid hygiene wipes
  • To evaluate ease of use for Blephademodex eyelid hygiene wipes
  • Adverse events are documented and analyzed.
02

Conditions studied

  • Demodex Blepharitis

Browse trials for

03

In context

Blepharitis

73 studies on the registry are indexed under Blepharitis; 9 are open to participants now.

This study's enrollment of 50 is below the median of 60 across 65 interventional studies indexed under Blepharitis.

Browse Blepharitis studies →

Lead sponsor

Laboratoires Thea is the lead sponsor of 64 studies on the registry; 6 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient > 18 years old, all genders
  • Able to read, to write and to fully understand German language
  • Good general health as determined by the investigator by medical history and physical appearance
  • Provision of written prior to inclusion
  • Moderate to Severe Blepharitis - grade ≥ 2 (Efron Scale)
  • Global discomfort score (GDS) ≥ 4
  • Proof of demodex infestation by at least ONE of the following:Demodex visible after lash manipulation;Cylindrical dandruff along the lash line; Lid margin itching; Madarosis

Exclusion criteria

Exclusion Criteria:

  • History of ocular trauma, ocular infection or intra-ocular inflammation within the 3 months before screening visit
  • History of ocular refractive surgery and any other ocular surgeries within 3 months before screening visit
  • History of ocular allergy or ocular herpes within the 3 months before screening visit
  • History of inflammatory corneal ulcer within the 6 months before screening visit
  • Sjogren syndrome or any other rheumatologic disease related dry eye
  • Concurrent treatment with other eye drops (anti-infectives, , prostaglandins (but artificial tears are ok).
  • Specific Exclusion Criteria for Women:Patient who verbally confirms pregnancy or lactation; woman who is not using a reliable method of (oral contraceptive, intra-uterine device, subcutaneous contraceptive implant, vaginal ring, patch or condom) and is not surgically sterilised
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Single-arm

    Device: Blephademodex

Interventions

  • DeviceBlephademodex

    During the first 28 days of the trial, subjects will use one Blephademodex® eyelid hygiene wipe every evening per eye to clean the eyelids of both their eyes. At the start of the second period the Investigator will assess based on the GDS if the condition is resolved and manage accordingly: subjects will either continue with this regime if GDS is unchanged (further treatment phase) or revert to Blephaclean wipes every evening instead (maintenance phase), again to clean the eyelids of both their eyes.

    Also known as: Blephaclean

06

What researchers measure

Primary outcomes

  1. Global Discomfort Score

    Change from Baseline at Day 28 The Global (overall) discomfort score (GDS) consists of a single question, which can be answered by the subject by choosing a value between 0 (no discomfort) and 10 (worst discomfort): Thinking about today, how would you rate the discomfort of your eyes?

    Time frame: Day 28

  2. Global Discomfort Score

    Change from D28 at Day 56

    Time frame: Day 56

Secondary outcomes

  1. Specific Blepharitis symptoms

    Symptoms will be rated by the patient on the day of visit using 10-grade scales (0 = none to 10 = severe) for each of the following items Severity of any eyelid itching today / Severity of lid redness today / Severity of eyelid swelling today / How severe was the eyelid crusting this morning when you woke up? / How severe is missing lashes today?

    Time frame: Day 56

  2. adapted Total Ocular Symptom Score (TOSS)

    8-item questionnaire with an overall score ranging from 0 ("none of the time") to 4 ("all of the time"). It contains of a single question concerning the frequency with which 8 different symptoms (itchy eyelids, eyelid redness, red eyes generally, swollen (puffy) eyes, tearing (eyes watering), crusting around the lashes, burning or stinging sensations and noticed eyelash loss) were experienced in the course of a week.

    Time frame: Day 56

  3. Symptom Assessment in Dry Eye (SANDE)

    Comprised of two questions: 1) How often do your eyes feel dry and/or irritated? And 2) How severe you feel your symptoms of dryness and/or irritation are? This questionnaire uses a 100 mm horizontal line as visual analogue scale (VAS) for each question to assess ocular discomfort and/or dryness experienced by the patients. In the SANDE questionnaire, frequency of symptoms ranges from "rarely" to "all of the time" and the severity of symptoms ranges from "very mild" to "very severe".

    Time frame: Day 56

  4. Demodex count

    Sideways 'pull' on 10 eyelashes - upper or lower lashes Extent (mites present? yes or no) and Severity/Intensity (1=1 tail; 2=2 tails; 3 =2+tails)

    Time frame: Day 56

  5. Ocular surface redness

    Efron scale

    Time frame: Day 56

  6. Lid margin redness/swelling

    Efron/custom scale

    Time frame: Day 56

  7. Cylindrical dandruff

    Lash line coverage (%) and severity (mild/moderate/severe)

    Time frame: Day 56

  8. Ocular surface staining

    Oxford scale; corneal only

    Time frame: Day 56

  9. Physician's impression and patient impression

    Answer the item 'the treatment has been sufficiently effective' on a 4-point scale (strongly disagree, disagree, agree, strongly agree)

    Time frame: Day 56

  10. Tolerability of the wipes

    Tolerability assessment by the physician and patient (0 = intolerable; 1 = somewhat tolerable; 2 = tolerable; 3 = fully tolerable)

    Time frame: Day 56

  11. Visual acuity

    Snellen eye chart

    Time frame: Day 56

  12. Assessment of ease of use

    as experienced by the subjects, rated on a five-point scale of "Very Difficult" to "Very Easy".

    Time frame: Day 56

07

Study locations

1 site
  • Consultation office
    Heidelberg, 69121, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04780165
Lead sponsor
Laboratoires Thea
Responsible party
Sponsor
First posted
Mar 3, 2021
Start date
Sep 11, 2019
Primary completion
Mar 13, 2020
Completion
May 14, 2020
Last update
Mar 3, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion